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The increase in prevalence of hypertension among youth over the past few decades has
been well documented. This increase in childhood hypertension prevalence is largely a
consequence of the childhood obesity epidemic.1–3 Based on current estimates, the overall
clinical prevalence of hypertension in children and adolescents, based on repeated measurements, is approximately 3.5%, with higher rates among adolescents.4,5 Among obese
adolescents, the rates are much higher. In a study of blood pressure (BP) and anthropometrics conducted on high school students, the prevalence of elevated BP (prehypertension
and hypertension combined) was over 30% in obese adolescent boys and between 23%
to 30%, depending on ethnicity, in obese adolescent girls.4 The greater prevalence of high
BP among obese adolescents compared to normal weight children has been confirmed in
several studies on different cohorts and populations.6–8 Obesity is defined as body mass
index (BMI) ≥95th percentile; and overweight is defined as >85th percentile to <95th
percentile. In normal weight children and adolescents there is a consistent positive rela-
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Abstract: Largely due to the childhood obesity epidemic, there has been an increase in the
prevalence of hypertension in children and adolescents. Obesity associated hypertension is
the most common hypertension phenotype among adolescents. Approximately 30% of obese
adolescents have elevated blood pressure (BP) or hypertension. Updated definitions of elevated
BP and hypertension in adolescents are now similar to definitions of BP status in adults. For
adolescents ≥13 years of age, elevated BP is 120 to 129/<80 mm Hg. Hypertension, stage 1, is
≥130 to 139/80 to 89 mm Hg, and hypertension, stage 2, is ≥140/90 mm Hg. BP measurements
over separate clinic visits are necessary to verify the diagnosis of elevated BP or hypertension.
Ambulatory BP monitoring, when available, provides confirmatory data on BP status. Causal
mechanisms for obesity associated hypertension include increased sympathetic nervous system
activity, increased renal sodium retention secondary to insulin resistance/hyperinsulinemia, and
obesity mediated inflammation. The primary treatment for obesity associated hypertension is
weight reduction with lifestyle changes in diet and physical activity. Although difficult to achieve,
even modest weight reduction can be beneficial. The diet should be rich in fruits, vegetables,
fiber, and low-fat dairy with reduction in salt intake. When lifestyle changes are insufficient to
achieve BP control, pharmacologic therapy is indicated to achieve a goal BP of <130/80 mm
Hg or <90th percentile, whichever is lower. Regular BP monitoring is necessary for ongoing
management of obesity associated hypertension in adolescents.
Keywords: adolescents, obesity, blood pressure, hypertension

Dovepress

Integrated Blood Pressure Control downloaded from https://www.dovepress.com/ by 147.140.233.14 on 11-Apr-2018
For personal use only.

Falkner

tionship of weight with BP throughout childhood growth and
development. However, excess adiposity disrupts this normal
relationship. In a cohort of healthy children and adolescents, Tu
et al.9 demonstrated that the prevalence of elevated BP (≥90th
percentile) increased by four-fold when BMI exceeded the 85th
percentile. These findings indicate that in addition to obesity,
overweight children and adolescents are also at increased risk
for elevated BP and hypertension.
The aforementioned studies applied a definition of
hypertension and prehypertension (elevated BP) based on the
2004 Fourth Report.10 The recent publication of an update
of the pediatric clinical practice guidelines (CPG) has modified the definition of hypertension in adolescents.11 In this
update, the reference tables on normative childhood BP data
were revised. Due to the confirmed effect of overweight and
obesity on an increase in BP throughout childhood, the new
BP tables are based on BP data only from normal weight
children and adolescents (BMI <85th percentile). Thus, age,
sex, and height adjusted BP levels for the 90th percentile,
designating elevated BP, and 95th percentile, designating
hypertension, are somewhat lower than the previous normative BP tables. For children less than 13 years of age, the
definitions of elevated BP (previously termed “prehypertension”) and hypertension remain the same. Elevated BP is
defined as average systolic and/or diastolic BP level that is
≥90th percentile and <95th percentile; and hypertension is
defined as average systolic and/or diastolic BP level that is
≥95th percentile on repeated visits. However, the definition
for elevated BP and for hypertension among adolescents
beginning at age 13 years is now different. The new BP
tables indicate that the 90th percentile for adolescents aged
13 years and older is close to a systolic BP of 120 mm Hg
and diastolic BP is <80 mm Hg; and the 95th percentile for
systolic BP at age 13 years is approximately 130 mm Hg.
These BP numbers mirror the threshold BP levels that are
used to define elevated BP and hypertension for adults in
the new CPG issued by the American College of Cardiology
and the American Heart Association.12 Therefore, the current
definition of BP classification and staging for adolescents ≥13
years of age is as follows: normal BP: <120/<80 mm Hg;
elevated BP: 120 to 129/<80 mm Hg; hypertension: ≥130/80
mm Hg. Stage 1 hypertension is 130 to 139/80 to 89 mm Hg;
stage 2 hypertension is ≥140/90 mm Hg.
These definitions of hypertension and elevated BP in adolescents age 13 years and above are simplified and harmonize
with the new adult definitions.11 This change should facilitate
detection of abnormal BP in adolescents. The change should
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also improve recognition of obesity associated hypertension
in adolescence.

Diagnosis of hypertension in
adolescents
The diagnosis of hypertension in adolescents require repeated
BP measurements that are ≥130/80 mm Hg. The average
of BP measurements in the hypertensive range on three
separate clinic visits are generally required for diagnosis of
hypertension in children and adolescents, unless the patient
is symptomatic. While automated BP measurement devices
are commonly used in clinical practices, BP measurement by
auscultation is the preferred measurement method to confirm
hypertension in children and adolescents. This is because the
normative BP data and BP tables are based on auscultated
BP measurements. Over the past decade, a substantial body
of data and clinical experience have been developed on the
use of ambulatory BP monitoring (ABPM) in childhood.13
The updated CPG recommends using ABPM to confirm
hypertension in adolescents who have repeated elevated BP
measurements.11 Approximately 25% of children with elevated clinic BP measurements have white coat hypertension,
a condition in which individuals have hypertension by clinic
BP measurements but are normotensive on out of office BP
measurements. When white coat hypertension is confirmed
by ABPM, further diagnostic testing or treatments to lower
BP are not indicated. However, periodic BP monitoring is
recommended. Masked hypertension is a clinical condition
in which clinic BP measurements are <95th percentile but
ambulatory BP measurements are ≥95th percentile. Masked
hypertension has been identified in both children and adolescents.14 Obese adolescents are at greater risk for masked
hypertension than non-obese adolescents.15 Normally there
is a BP decrease, or dip, from the awake phase to the sleep
phase on ABPM. Obese adolescents are also at greater risk
for abnormal nocturnal dipping, where the decrease in BP
during the sleep period is <10% of the awake period ABPM.16
Therefore, ABPM would be useful in evaluating BP status in
obese adolescents with elevated BP.

Insulin resistance and metabolic
syndrome
Insulin resistance (the inverse of insulin sensitivity) is
generally defined as a decrease in insulin mediated glucose uptake in response to physiological (endogenous) or
exogenous insulin.17 A biologic consequence of impaired
insulin mediated glucose uptake is greater insulin secretion,
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or compensatory hyperinsulinemia, to achieve glucose control. The resulting chronic hyperinsulinemia leads to other
potential dysregulatory metabolic and physiologic effects
including impaired glucose tolerance, and dyslipidemia.
While insulin resistance is present in many clinical conditions, insulin resistance is the core abnormality underlying
metabolic syndrome,18 a condition with heightened risk
for diabetes and cardiovascular disease among adults.19,20
Because insulin resistance is difficult to quantify clinically,
the concept of metabolic syndrome provides a strategy to
identify underlying insulin resistance among individuals
with multiple cardiovascular/metabolic risk factors. Despite
some variation in the exact definition of metabolic syndrome,
the usual definition, from the National Cholesterol Education Program Adult Treatment Panel III (ATPIII)21 is three
of the following five criteria: 1) visceral obesity, based on
waist circumference, 2) elevated BP, 3) abnormal glucose
tolerance, 4) elevated plasma triglyceride, and 5) low high
density lipoprotein (HDL-cholesterol). Using ATPIII criteria
modified for children, Cook et al.22 examined the prevalence
of metabolic syndrome in children from the National Health
and Nutrition Examination Survey (NHANES) data periods
1988–1994. Modifications of criteria for children included
BP ≥90th percentile, waist circumference >95th percentile
or BMI ≥95th percentile, and triglyceride level ≥95th percentile on childhood reference table. In this study, metabolic
syndrome was identified in 4.2% of children aged 5 to 18
years. However, among obese adolescents, the prevalence
was as high as 28.7%. Another study on a cohort of obese
children and adolescents found elevated BP (≥90th percentile), confirmed by repeated BP measurement, in 37% of the
cohort. More boys with elevated BP had low HDL-cholesterol
compared to boys with normal BP.23 Weiss et al.24 reported
that the prevalence of metabolic syndrome increased with the
severity of obesity and reached 50% among severely obese
youth. Obesity is strongly associated with insulin resistance,
which is manifest by relative hyperinsulinemia.25 Obesity and
elevated BP are two criteria of metabolic syndrome. It is also
evident that other components of metabolic syndrome are
frequently identified among obese adolescents who express
the phenotype of obesity with elevated BP. Therefore, it can
be clinically useful to screen obese adolescents with elevated
BP for plasma lipids and glucose levels.

Mechanisms for obesity associated
hypertension
Various theories have been proposed to explain a causal role
for obesity in elevated BP or hypertension. One theory is that
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hyperinsulinemia, as a consequence of insulin resistance,
activates the sympathetic nervous system (SNS).26 A potential mechanism for SNS activation could be adipose tissue
production of leptin, which is commonly elevated in obese
individuals.27,28 Further support for heightened SNS activity
in obese hypertensive adolescents was developed using data
from 24 hour ABPM. Compared to normal weight hypertensive adolescents, obese hypertensive adolescents have higher
heart rates and greater variability during ABPM, suggesting a
hyperkinetic hemodynamic condition.8,29,30 While heightened
SNS activity is likely present among obese adolescents, it is
not the only pathway involved in the association of obesity
with elevated BP.
Dietary sodium has been implicated in the association of
excess adiposity and elevated BP in children and adolescents.
Rosner et al.3 examined childhood BP trends from sequential
NHANES data periods 1988 to 2008. These investigators
demonstrated a progressive increase in both the BP level
and in the prevalence of high BP in children and adolescents.
In their analyses the predictors of increasing BP level and
prevalence of high BP were higher BMI and waist circumference, and greater dietary sodium intake. In another study on
NHANES data Yang et al.31 examined sodium intake on 6,000
children and adolescents, of whom 37% were overweight
or obese. The overall average sodium intake was 3.387 mg/
day. The cohort was then stratified according to quartiles of
sodium intake, and within each quartile participants were
grouped as normal weight or overweight/obese. For the
entire cohort, the odds ratio (OR) for risk of elevated BP/
hypertension in the highest sodium quartile compared to the
lowest quartile was 2.0. However, among the overweight/
obese participants, the adjusted OR for risk of elevated BP/
hypertension in the highest sodium quartile increased to 3.5;
P = 0.013. Results of these recent epidemiologic studies
indicate that obese children and adolescents have greater
BP sensitivity to sodium intake compared to normal weight
children and adolescents.
The relative hyperinsulinemia associated with obesity
in children, as well as adults, can contribute to greater BP
sensitivity to sodium intake. Both clinical and experimental
research demonstrate that insulin upregulates renal tubular
sodium transport. Higher circulating plasma insulin levels
can augment sodium reabsorption in the distal tubules which
would increase BP. This concept is in line with the results of
a study by Rocchini et al.32 on a sample of obese adolescents
with elevated BP. BP was measured in the obese adolescents
following 2 weeks on a high salt diet; and BP measurements
were obtained again following 2 weeks on a low salt diet.
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There was a significant reduction in BP following the low
salt diet indicating BP sensitivity to sodium. A weight reduction intervention was then provided for the obese adolescent
participants over several weeks. Following weight reduction
efforts, the high and low salt procedures were repeated.
Among the obese adolescents without any weight reduction, the BP response from high to low salt procedures were
unchanged. Whereas, among obese adolescents who achieved
modest weight reduction, there was a reduction in the BP
change from high to low salt diet supporting the concept that a
decrease in adiposity resulted in a reduction in BP sensitivity
to sodium. Despite limitations in the literature on the role of
dietary salt and BP in youth, the available evidence support
a contribution of high sodium intake on increases BP among
children and adolescents who are overweight or obese.
Another theory to explain the obesity-hypertension
association in both adolescents and adults is alterations
in microvascular function and structure mediated through
inflammation. Obesity is associated with elevated levels of
pro-inflammatory cytokines, including C-reactive protein
(CRP) and interleukin-6 (IL-6).33 Similar elevations of
these cytokines have been reported in obese adolescents.24,34
Obesity is associated with an accumulation of macrophages
in adipose tissue, which may contribute to obesity-related
inflammation.35 Support for a causal role of inflammation in
development of hypertension is largely based on experimental studies that focus on endothelial dysfunction.36,37 When
human vascular endothelial cells are exposed to CRP in vitro,
there is a resulting decrease in expression of endothelial nitric
oxide synthase with subsequent attenuation of vasodilation
responses.38 Experimental works have investigated a role of
perivascular adipose tissue (PVAT) in the signaling of inflammatory cytokines. Excess PVAT contributes to endothelial
dysfunction and increases vascular smooth muscle tone.39,40
This concept was investigated by Greenstein et al.41 who used
PVAT from lean and obese humans. In in vitro experiments,
the investigators found that, compared to PVAT from lean
individuals, vasodilatory capacity was lost in PVAT from
obese subjects; and in the obese tissues there was concurrent
expression of mediators of inflammation and oxidative stress.
It is plausible that microvascular dysfunction, mediated
by PVAT-derived inflammation could contribute to insulin
resistance and capillary rarefaction, both of which create a
platform for increased vascular resistance and hypertension.
The potential causal mechanisms underlying obesity associated hypertension among adolescents are likely overlapping
with possible synergistic action. Despite gaps in complete
understanding of fundamental mechanisms, it is clear that

36

Powered by TCPDF (www.tcpdf.org)

submit your manuscript | www.dovepress.com

Dovepress

obesity is associated with insulin resistance with compensatory hyperinsulinism; and that in adolescence, this condition
has many adverse consequences including elevated BP and
premature adult onset cardiovascular disease.

Management of adolescents with
obesity and elevated BP
Management of adolescents with elevated BP or suspected
hypertension include confirming the BP status, evaluation
for other obesity-related risk factors, and interventions to
achieve a more optimal BP. For elevated BP (120/<80 to
129/<80 mm Hg) or hypertension (≥130/80 mm Hg) measured during a clinical visit, repeated BP measurements are
needed at the time of the visit or on subsequent visits when
the patient is without symptoms. Repeat BP measurements
by auscultation are preferred.11 Usually, three separate visits
for accurate BP ascertainment are needed to confirm that
the average BP is normal, elevated, or hypertensive. Due to
the known prevalence of white coat hypertension, ABPM is
now recommended to confirm the BP status. ABPM is also
informative for obese adolescents who have greater risk
for masked hypertension.15 For adolescents with confirmed
elevated BP or hypertension, additional screening for obesityrelated risk factors including plasma lipids and glucose can be
informative of overall health status. Detection of dyslipidemia
or impaired glucose tolerance would indicate metabolic syndrome which serves to intensify efforts on weight reduction.
A sleep history is useful, especially in very obese adolescents,
as sleep disordered breathing or obstructive sleep apnea is
often associated with hypertension in adolescents.11 Further
diagnostic studies are generally not necessary during the
initial evaluation unless the patient has a history of previous
renal disorders, or a family history of chronic kidney disease.
The major intervention in management of hypertension in
obese adolescents is weight reduction. Unfortunately, weight
reduction is also very difficult to achieve for obese adolescents, as well as for obese adults. Lifestyle interventions that
include changes in diet and increasing physical activity are
key for weight reduction and, when achieved over a period
of time, have been shown to lower BP in children and adolescents.42,43 For stage 1 hypertension, lifestyle interventions
with BP monitoring should be tried for 6 to 12 months.11
The dietary approach to stop hypertension (DASH)
diet plan has demonstrated impressive reductions in BP in
adults.44,45 The DASH diet includes high intake of fruits,
vegetables, whole grains, and low-fat dairy along with
reductions in sodium intake. A small clinical trial tested the
DASH diet versus routine nutritional counseling (RC) in a
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sample of hypertensive adolescents. Following 3 months on
the diets there was significantly greater BP reduction in the
DASH diet group compared to the RC group; and this change
persisted for 6 months.46 The DASH diet is an appropriate
style diet to recommend for obese adolescents. Reductions
in dietary sodium intake should be incorporated into the
DASH diet plan, especially because average sodium intake of
adolescents is well above recommended levels of 2,500 mg/
day. To achieve a reduction in sodium intake it is necessary
to limit processed, prepared, and “fast” foods; which are food
items generally preferred by adolescents.
Physical activity is beneficial in weight reduction efforts
and also improves cardiovascular fitness. Any type of exercise
is beneficial and can include aerobic training, resistance training or combined training.47 Moderate to vigorous physical
activity should be encouraged, with a goal of 30 to 60 minutes
on at least 5 days a week. For obese adolescents, the increase
in physical activity needs to be gradual to avoid injury, and
should include activities that are pleasant and sustainable.
While most obese adolescents are not competitive athletes,
they should not be restricted from participating in organized
sports programs. However, it is recommended that athletic
participation by adolescents who have stage 2 hypertension
have their participation in high-static competitive sports
restricted until their BP is controlled with lifestyle modification and/or pharmacologic therapy.48
Pharmacologic therapy to lower BP is indicated for
hypertensive adolescents when there is insufficient or no
response to lifestyle interventions. Drug treatment is also
indicated for adolescents with symptomatic hypertension or
persistent stage 2 hypertension. Therefore, pharmacologic
therapy should be considered earlier than 6 months of lifestyle
interventions in obese adolescents with stage 2 hypertension.
With stage 2 hypertension, pharmacologic treatment can be
considered following 1 to 3 months of lifestyle interventions,
but lifestyle interventions should continue in conjunction
with drug treatment. Prior to beginning antihypertension
medications an echocardiogram should be obtained for
assessment of possible target organ damage. A finding of
left ventricular hypertrophy (LVH) on echocardiogram is
evidence of hypertensive mediated target organ damage and
warrants further effort to lower BP.11 It should be noted that
obesity also contributes to LVH, an effect that is independent
of BP.49,50 Therefore, both high BP and obesity contribute to
LVH, and BP reduction alone may be insufficient to reduce
LVH. It is also prudent to consider if there could be an underlying secondary cause of the hypertension, in addition to the
obesity. Standard screening would be a renal ultrasound and
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blood studies including a complete blood count, electrolytes,
creatinine, renin, and aldosterone.
Recommendations on antihypertensive drug therapy in
children and adolescents were updated in the recent CPG.11
Drug treatment should begin with a single agent at the low
end of the dosing range. For initial treatment, the preferred
choices are angiotensin converting enzyme (ACE-inhibitor),
angiotensin receptor blocking (ARB) agent, long-acting calcium channel blocker (CCB), or a thiazide diuretic. The dose
can be up-titrated every 2 to 4 weeks, with BP monitoring
every 4 to 6 weeks until the BP is normalized (<130/<80 mm
Hg or <90th percentile, whichever is lower on the new BP
tables).11 If BP response is insufficient at maximum dose of a
single agent, a second drug can be added. A thiazide diuretic
is generally the preferred second drug choice. For African
American adolescents, who may not have a brisk response to
ACE-inhibitors, the initial dose could be somewhat higher.
If LVH is present, ACE-inhibitors or ARBs are initial drug
choice. However, ACE-inhibitors and ARBs can have teratogenic effects on fetal development and are contraindicated
in pregnancy. Adolescent girls with childbearing potential
should be counseled on the possible risks of these drugs,
and if there is a risk of pregnancy an alternative drug, such
as a CCB, should be prescribed. Beta-blocking agents are
generally not recommended as initial drug choices in obese
adolescents, because many of these drugs have an adverse
effect on insulin resistance. If the BP control is not achieved
with three drugs, non-compliance should be considered or
possibly a missed diagnosis of secondary hypertension.
Repeat BP monitoring with ABPM can be useful in these
situations. While drug therapy may be necessary to achieve
BP control, efforts to reduce excess body weight with lifestyle
changes should be continued. If weight loss is achieved, it
may become possible to decrease or even withdraw drug
therapy. However, even with withdrawal of drug treatment,
regular BP monitoring should continue.

Summary
Hypertension associated with obesity is commonly found in
adolescents. Approximately 30% of adolescents with obesity
have elevated BP or hypertension. Overweight and obese adolescents have greater BP sensitivity to dietary salt compared
to normal weight adolescents. The relative endogenous hyperinsulinemia associated with obesity contributes to the salt
sensitivity. While there are other possible mechanisms that
contribute to elevated BP/hypertension in obese adolescents,
the optimal treatment is weight reduction. Although achieving a normal body weight is extremely difficult, even modest
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reductions in weight can be beneficial. Dietary changes with
a shift from processed high salt foods to a diet rich in fruits,
vegetables, fiber, and low fat dairy along with a reduction
in sodium intake are important initial therapy along with
an increase in physical activity. If BP reduction by lifestyle
change is not achieved, drug therapy can be beneficial in
achieving control of BP. Initial BP monitoring, including
ABPM is necessary to confirm hypertension status. And
when BP control is achieved, BP monitoring should continue
to ensure that BP control continues through adolescence.
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